| Evaluating CAR‐T cell therapy in a hypoxic 3D tumor model Y Ando, EL Siegler, HP Ta, GE Cinay, H Zhou, KA Gorrell, H Au, ... Advanced healthcare materials 8 (5), 1900001, 2019 | 90 | 2019 |
| A cost-effective micromilling platform for rapid prototyping of microdevices DP Yen, Y Ando, K Shen Technology 4 (04), 234-239, 2016 | 40 | 2016 |
| A microdevice platform recapitulating hypoxic tumor microenvironments Y Ando, HP Ta, DP Yen, SS Lee, S Raola, K Shen Scientific Reports 7 (1), 15233, 2017 | 35 | 2017 |
| A carcinoembryonic antigen-specific cell therapy selectively targets tumor cells with HLA loss of heterozygosity in vitro and in vivo ML Sandberg, X Wang, AD Martin, DP Nampe, GB Gabrelow, CZ Li, ... Science Translational Medicine 14 (634), eabm0306, 2022 | 31 | 2022 |
| CCR2-targeted micelles for anti-cancer peptide delivery and immune stimulation N Trac, LY Chen, A Zhang, CP Liao, C Poon, J Wang, Y Ando, J Joo, ... Journal of controlled release 329, 614-623, 2021 | 28 | 2021 |
| Spatial regulation of mitochondrial heterogeneity by stromal confinement in micropatterned tumor models HM Begum, HP Ta, H Zhou, Y Ando, D Kang, K Nemes, CF Mariano, ... Scientific reports 9 (1), 11187, 2019 | 19 | 2019 |
| Engineered in vitro tumor models for cell-based immunotherapy Y Ando, C Mariano, K Shen Acta biomaterialia 132, 345-359, 2021 | 18 | 2021 |
| Engineering a vascularized hypoxic tumor model for therapeutic assessment Y Ando, JM Oh, W Zhao, M Tran, K Shen Cells 10 (9), 2201, 2021 | 12 | 2021 |
| Non-invasive optical biomarkers distinguish and track the metabolic status of single hematopoietic stem cells H Zhou, L Nguyen, C Arnesano, Y Ando, M Raval, JT Rodgers, S Fraser, ... Iscience 23 (2), 2020 | 10 | 2020 |
| Extensive functional comparisons between chimeric antigen receptors and T cell receptors highlight fundamental similarities X Wang, AD Martin, KR Negri, ME McElvain, J Oh, ML Wu, WH Lee, ... Molecular Immunology 138, 137-149, 2021 | 5 | 2021 |
| 229 A2B530, an autologous CEA-directed Tmod T-cell therapy with an inhibitory receptor gated by HLA-A* 02 to target colorectal, pancreatic, and lung cancer JR Hecht, M Sandberg, X Wang, A Martin, D Nampe, G Gabrelow, C Li, ... Journal for ImmunoTherapy of Cancer 10 (Suppl 2), 2022 | 4 | 2022 |
| Bioengineering tools for probing intracellular events in T lymphocytes X Zhang, CF Mariano, Y Ando, K Shen WIREs mechanisms of disease 13 (4), e1510, 2021 | 2 | 2021 |
| Integrin adjunct therapy for melanoma KL Andarawewa, K Moissoglu, CS Lee, Y Ando, M Yu, P Debnath, ... Pigment cell & melanoma research 28 (1), 114, 2015 | 2 | 2015 |
| Compositions and methods for treating her2 positive cancers A Yuta, OH Julyun, H Xu, CA Kamb US Patent App. 18/340,435, 2024 | | 2024 |
| Compositions and methods for treating HER2 positive cancers A Yuta, OH Julyun, H Xu, CA Kamb US Patent 11,730,764, 2023 | | 2023 |
| The modular Tmod dual_receptor system exploits tumor deletions to achieve robust tumor-selective cytotoxicity H Xu, A Hamburger, Y Ando, G Asuelime, K Bolanos, M Daris, ... Cancer Research 82 (12_Supplement), 2751-2751, 2022 | | 2022 |
| 122 A powerful, precise targeting system controlled by tumor deletions transforms CEA and MSLN CAR-T cells into tumor-selective agents A Hamburger, H Xu, Y Ando, G Asuelime, K Bolanos-Ibarra, M Daris, ... Journal for ImmunoTherapy of Cancer 9 (Suppl 2), 2021 | | 2021 |
| Microdevice platform recapitulating hypoxic tissue microenvironments K Shen, A Yuta, D Yen, H Ta US Patent App. 17/071,329, 2021 | | 2021 |
| Microdevice platform recapitulating hypoxic tissue microenvironments K Shen, A Yuta, D Yen, H Ta US Patent 10,829,730, 2020 | | 2020 |
| Understanding mitochondrial heterogeneity and metastatic potential in micro-engineered tumor models HM Begum, K Nemes, Y Ando, M Yu, K Shen CLINICAL & EXPERIMENTAL METASTASIS 36 (2), 145-146, 2019 | | 2019 |
